5-fluoro-8,8-dimethyl-7,9-dihydro-3H-pyridazino[4,5-a]pyrrolizin-4-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并[3，4-d]哒嗪
• 英文名称: 5-fluoro-8,8-dimethyl-7,9-dihydro-3H-pyridazino[4,5-a]pyrrolizin-4-one
• 化学式: C₁₁H₁₂FN₃O
• 分子量: 221.23
• InChiKey: IRCRLBDECYDPSS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  46.4
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] PYRAZOLE CARBOXAMIDE COMPOUNDS FOR USE IN THE TREAMENT OF DISORDERS MEDIATED BY BRUTON'S TYROSINE KINASE (BTK)<br/>[FR] COMPOSÉS DE PYRAZOLE-CARBOXAMIDE DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE TROUBLES MÉDIÉS PAR LA TYROSINE KINASE DE BRUTON (BTK)
  申请人：HOFFMANN LA ROCHE

  公开号：WO2016050921A1

  公开（公告）日：2016-04-07

  Pyrazole carboxamide compounds of Formula (I) are provided (X and R1-R6 are as defined in the claims), with various substituents, and including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk, and for treating cancer and immune disorders such as inflammation mediated by Btk. Methods of using compounds of Formula (I) for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  提供了式（I）的吡唑羧酰胺化合物（其中X和R1-R6如权利要求中所定义），具有各种取代基，包括立体异构体、互变异构体和其药学上可接受的盐，用于抑制Btk，并用于治疗癌症和由Btk介导的炎症等免疫紊乱。公开了使用式（I）化合物进行哺乳动物细胞中的体外、体内和体内诊断以及治疗这类疾病或相关病理条件的方法。
• US8716274B2
  申请人：——

  公开号：US8716274B2

  公开（公告）日：2014-05-06
• [EN] HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS WITH ELECTROPHILIC FUNCTIONALITY<br/>[FR] COMPOSÉS DE PYRIDONE HÉTÉROARYLIQUE ET D'AZA-PYRIDONE À FONCTIONNALITÉ ÉLECTROPHILE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015082583A1

  公开（公告）日：2015-06-11

  Heteroaryl pyridone and aza-pyridone amide compounds with electrophilic functionality of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk, and for treating cancer and immune disorders such as inflammation mediated by Btk. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.